Literature DB >> 20298406

Sarcoidosis-associated pulmonary hypertension: acute vasoresponsiveness to inhaled nitric oxide and the relation to long-term effect of sildenafil.

Nils Milman1, Claus Bo Svendsen, Martin Iversen, Regitze Videbaek, Jørn Carlsen.   

Abstract

BACKGROUND: Severe pulmonary sarcoidosis is often complicated by pulmonary hypertension (PH) caused by different pathophysiological mechanisms.
OBJECTIVES: To assess the acute vasoresponsiveness in patients with sarcoidosis and PH and the relation to the therapeutic effect of sildenafil.
METHODS: A retrospective chart review of 25 patients with recalcitrant pulmonary sarcoidosis being evaluated for lung transplantation at our centre. Haemodynamics were evaluated by right heart catheterisation in 24 patients of whom 19 had PH. Eight of the 19 patients received vasodilator challenge with inhaled nitric oxide (iNO).
RESULTS: The study group of eight patients (seven men) had a median age of 51 years (range 38 years-58 years). During iNO we observed a reduction in all patients' mean pulmonary arterial pressure (MPAP) of median 9 mmHg (range 1 mmHg-20 mmHg) (P = 0.01) and in all patients' pulmonary vascular resistance of median 2.0 Wood Units (0.7 Wood Units-5.8 Wood Units) (P = 0.01). Acute vasoresponsiveness defined as reduction in MPAP of >or=10 mmHg to a MPAP of <or=40 mmHg without reduction in cardiac output was achieved in two of eight patients. Seven patients were subsequently started on sildenafil and had haemodynamics measured during treatment. There was no relationship between the acute vasoresponsiveness and the response to treatment. One patient had similar responses, but in six patients, the responses were reversed.
CONCLUSIONS: Approximately a quarter of the tested patients with end-stage pulmonary sarcoidosis and PH displayed acute vasoresponsiveness to iNO. However, the degree of vasoresponsiveness appears to be a poor predictor of the response to treatment of PH with sildenafil.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20298406     DOI: 10.1111/j.1752-699X.2008.00120.x

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  6 in total

1.  Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: a retrospective case series.

Authors:  Catherine A Bonham; Justin M Oldham; Mardi Gomberg-Maitland; Rekha Vij
Journal:  Chest       Date:  2015-10       Impact factor: 9.410

2.  Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis.

Authors:  M C Schimmelpennink; D B Meek; A D M Vorselaars; L C M Langezaal; C H M van Moorsel; J J van der Vis; M Veltkamp; J C Grutters
Journal:  Respir Res       Date:  2022-06-25

3.  Elevated pulmonary arterial systolic pressure in patients with sarcoidosis: prevalence and risk factors.

Authors:  Aggeliki Rapti; Vasileios Kouranos; Elias Gialafos; Konstantina Aggeli; John Moyssakis; Anastasios Kallianos; Charalampos Kostopoulos; Ourania Anagnostopoulou; Petros P Sfikakis; Athol U Wells; George E Tzelepis
Journal:  Lung       Date:  2012-12-11       Impact factor: 2.584

Review 4.  Group 5 Pulmonary Hypertension: The Orphan's Orphan Disease.

Authors:  Sara Kalantari; Mardi Gomberg-Maitland
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

5.  Sarcoidosis-associated Pulmonary Hypertension: Pathophysiology, Diagnosis, and Treatment.

Authors:  Heng Duong; Catherine A Bonham
Journal:  Clin Pulm Med       Date:  2018-03

6.  Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis.

Authors:  Shijie Zhang; Xiang Tong; Tianli Zhang; Dongguang Wang; Sitong Liu; Lian Wang; Hong Fan
Journal:  Front Cardiovasc Med       Date:  2022-01-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.